Latest Product Updates and Feature Enhancements on Valgen Inc.

 

Valgen earns CE mark for mitral valve repair system

Valgen Medtech received CE mark approval for its DragonFly transcatheter mitral repair system, covering functional mitral regurgitation (FMR). This positions DragonFly as the first such device from C...hina approved in Europe for both DMR and FMR. The system features transfemoral transcatheter edge-to-edge repair with multiple clip sizes and high procedural success rates.

Read on →
 

The Valgen Medtech DragonFlyTM System Receives EU Approval for FMR ...

Valgen Medtech's DragonFly™ Transcatheter Mitral Valve Repair System has received CE mark approval in the European Union for treating Functional Mitral Regurgitation (FMR). This marks the first trans...catheter mitral valve repair device from China to receive EU approval for both DMR and FMR. The system is supported by robust clinical evidence and is already in use in 15 countries.

Read on →

Mergers, Acquisitions, and Business Moves by Valgen Inc.

 

Valgen Medtech

Kindly Medical to take control of Chinese heart-device unicorn Valgen in $170 million deal - Dealroom

Shanghai Kindly Medical Instruments is acquiring a controlling stake in Valgen Medtech, a Hangzhou-based company specializing in interventional heart treatments, for $172.9 million. This acquisition ...is part of a consolidation trend in China's medical-device sector, aiming to secure control of homegrown unicorns with regulatory-approved products.

Read on →
 

Shanghai INT Medical to Acquire Stake in Valgen

Shanghai INT Medical plans to acquire a stake in Valgen, indicating a strategic investment in the software company.

Read on →
 

Shanghai INT Medical to acquire Valgen stake for $107.8m

Shanghai INT Medical Instruments Co., Ltd. has agreed to acquire a 23.18% stake in Valgen Holding Corporation for $107.8 million. Valgen Medtech, a subsidiary, specializes in treatments for atriovent...ricular valve diseases. The acquisition aims to enhance Shanghai INT Medical's competitiveness in the structural heart disease sector.

Read on →